A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Terminated · Phase 2 · NCT06867094
Conditions: Colitis Ulcerative
At a glance
- Research payments reported, 2025
- $19,496
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 170
About the trial
- Sponsor
- Sanofi
- Tested
- SAR441566 (drug), SAR441566 matching Placebo (drug)
- Dates
- Started 2025-03-28; completion 2026-10-12
- Results posted
- Not yet
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of tre…
From ClinicalTrials.gov, last updated 2026-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $19,496 in research payments for this study in 2025 (48 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $19,496
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.